Patent · US Active

Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases

US8133895B2 · kind B2 · utility

7Cited by

0References

13Claims

0Family size

Assignee

Janssen Pharmaceutica NA · BE

Inventors

Martin James Inglis Andrews · Mechelen, BE
Mark Stuart Chambers · Watford, GB
Wolfgang Schmidt · Frankfurt, DE
Gregory Bar · Mechelen, BE

Key dates

Filing date	May 7, 2008
Grant date	Mar 13, 2012
Priority date	—
Expiry date	May 7, 2028

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P29/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Novel fused pyrazine compounds are disclosed that have a formula represented by the following:The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, inflammation, rheumatoid arthritis and others.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.